Detailed price information for Relay Therapeutics Inc (RLAY-Q) from The Globe and Mail including charting and trades.

Detailed price information for Relay Therapeutics Inc (RLAY-Q) from The Globe and Mail including charting and trades.

Discover how intelligent protection relays are evolving beyond fault detection to deliver real-time insights, power quality ...

Relay Therapeutics (RLAY) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more ...

Hansoh’s olatorepatide achieved 19% weight loss at 48 weeks in a Phase 3 trial in China, handing partner Regeneron a glimmer of hope for a pipeline in desperate need of reinvigoration. Regeneron’s ...

Relay Therapeutics develops precision medicines targeting oncology and genetic diseases, leveraging proprietary computational ...

Novo Nordisk’s GLP-1/amylin combo has failed to beat Eli Lilly’s obesity blockbuster Zepbound in a phase 3 weight loss study, further denting the Danish pharma’s attempts to reclaim its obesity crown.

Under the efficacy estimand, patients treated with CagriSema achieved a 23.0% weight loss compared with 25.5% in those treated with tirzepatide. Topline results were ...

SACRAMENTO, Calif., Feb. 19, 2026 /PRNewswire/ -- KilgourMD, the dermatologist-founded scalp health and hair growth brand, created by Stanford-trained board-certified dermatologist Dr. James Kilgour, ...

Biomed Industries, Inc. Announces Two NA-931 Phase 3 Trials, Targeting Durable Weight Loss & Lean-Mass Preservation at JP Morgan Week 2026 Advancing NA-931, the first oral quadruple receptor ...